|
|
||||||||
1 Gene Therapy and Therapeutics Branch, NIDCR, NIH, DHHS, Bethesda, Maryland 20892, USA
2 Department of Clinical Immunology and Rheumatology, Academic Medical Center, Amsterdam, The Netherlands
3 Pediatric and Reproductive Endocrinology Branch, NICHD, NIH, DHHS, Bethesda, Maryland 20892, USA
(Requests for offprints should be addressed to B J Baum; Email: bbaum{at}dir.nidcr.nih.gov)
Salivary glands (SGs) exhibit several important features which are also common to endocrine glands: self-containment due to a surrounding capsule, highly efficient protein production and the ability to secrete proteins into the bloodstream. We have hypothesized that SGs are potentially useful as gene transfer targets for the correction of inherited monogenetic endocrine disorders. In the present communication, we extend our studies and attempt to test our hypothesis by comparing the efficacy of two commonly used viral vectors and the resulting serum and salivary distribution of transgene encoded hormones.
A low dose (5 x109 particles) of either an adenoviral serotype 5 (Ad5) vector encoding the human erythropoietin (hEPO) cDNA or an adeno-associated virus sero-type 2 (AAV2) vector encoding either the hEPO or human growth hormone (hGH) cDNA was administered to individual submandibular SGs of Balb/c mice. Serum and salivary hEPO and hGH levels were determined at defined time points. Two additional recombinant viruses encoding enhanced green fluorescence protein (GFP) were also used (AdGFP and AAVGFP) in order to perform immunohistochemical analyses of transgenic protein localization in SG sections post-administration.
AAV2 vectors led to stable gene transfer unlike the results with the Ad5 vectors. Indeed, in one mouse we observed hEPO production for a period of two years after administration of AAVhEPO to SGs. hEPO, which is a constitutive pathway secretory protein, was readily secreted into the bloodstream from the SGs, yielding therapeutically adequate serum levels. Conversely, hGH, a regulated secretory pathway protein, was preferentially secreted into saliva.
SGs may be an attractive candidate target tissue for gene therapeutics of some monogenetic endocrine deficiency disorders. At present, AAV2 vectors seem particularly useful for such applications, and transgenes encoding constitutive secretory pathway hormones are more suitable for this application with SGs than those encoding regulated secretory pathway hormones.
This article has been cited by other articles:
![]() |
A. P. Cotrim and B. J. Baum Gene Therapy: Some History, Applications, Problems, and Prospects Toxicol Pathol, January 1, 2008; 36(1): 97 - 103. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Venkatesh, J. Tan, S.-U. Gorr, and D. S. Darling Isoproterenol increases sorting of parotid gland cargo proteins to the basolateral pathway Am J Physiol Cell Physiol, August 1, 2007; 293(2): C558 - C565. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Mullins, L. J. Mullins, D. R. Dunbar, W. J. Brammar, K. W. Gross, and S. D. Morley Identification of a human ortholog of the mouse Dcpp gene locus, encoding a novel member of the CSP-1/Dcpp salivary protein family Physiol Genomics, December 13, 2006; 28(1): 129 - 140. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |